-
公开(公告)号：US20090220417A1
公开(公告)日：2009-09-03
申请号：US12420747
申请日：2009-04-08
IPC分类号： A61K39/395 , A61K51/00 , A61K49/00
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/76 , C07K2317/92 , Y10S514/885 , Y10S514/886
摘要： The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
摘要翻译： 本发明涉及治疗瘙痒症的方法，包括但不限于接触性皮炎，特应性皮炎，药物诱导的延迟型皮肤过敏反应，毒性表皮坏死松解症，皮肤T细胞淋巴瘤，大疱性类天疱疮，斑秃，白癜风，痤疮红斑痤疮， 腮腺炎，硬皮病，单纯疱疹病毒或其组合通过施用IL-31单克隆抗体。 本发明进一步提供产生单克隆抗体的杂交瘤。
-
公开(公告)号：US20110293514A1
公开(公告)日：2011-12-01
申请号：US13185130
申请日：2011-07-18
IPC分类号： A61K51/10 , A61P17/04 , A61K39/395
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/76 , C07K2317/92 , Y10S514/885 , Y10S514/886
摘要： The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
摘要翻译： 本发明涉及治疗瘙痒症的方法，包括但不限于接触性皮炎，特应性皮炎，药物诱导的迟发型皮肤过敏反应，毒性表皮坏死松解症，皮肤T细胞淋巴瘤，大疱性类天疱疮，斑秃，白癜风，痤疮红斑痤疮， 腮腺炎，硬皮病，单纯疱疹病毒或其组合通过施用IL-31单克隆抗体。 本发明进一步提供产生单克隆抗体的杂交瘤。
-
公开(公告)号：US08017122B2
公开(公告)日：2011-09-13
申请号：US12420747
申请日：2009-04-08
IPC分类号： A61K39/395
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/76 , C07K2317/92 , Y10S514/885 , Y10S514/886
摘要： The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
摘要翻译： 本发明涉及治疗瘙痒症的方法，包括但不限于接触性皮炎，特应性皮炎，药物诱导的延迟型皮肤过敏反应，毒性表皮坏死松解症，皮肤T细胞淋巴瘤，大疱性类天疱疮，斑秃，白癜风，痤疮红斑痤疮， 腮腺炎，硬皮病，单纯疱疹病毒或其组合通过施用IL-31单克隆抗体。 本发明进一步提供产生单克隆抗体的杂交瘤。
-
公开(公告)号：US07531637B2
公开(公告)日：2009-05-12
申请号：US11430066
申请日：2006-05-08
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/76 , C07K2317/92 , Y10S514/885 , Y10S514/886
摘要： The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
摘要翻译： 本发明涉及治疗瘙痒症的方法，包括但不限于接触性皮炎，特应性皮炎，药物诱导的延迟型皮肤过敏反应，毒性表皮坏死松解症，皮肤T细胞淋巴瘤，大疱性类天疱疮，斑秃，白癜风，痤疮红斑痤疮， 腮腺炎，硬皮病，单纯疱疹病毒或其组合通过施用IL-31单克隆抗体。 本发明进一步提供产生单克隆抗体的杂交瘤。
-
公开(公告)号：US08568723B2
公开(公告)日：2013-10-29
申请号：US13185130
申请日：2011-07-18
IPC分类号： A61K39/395
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/76 , C07K2317/92 , Y10S514/885 , Y10S514/886
摘要： The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
摘要翻译： 本发明涉及治疗瘙痒症的方法，包括但不限于接触性皮炎，特应性皮炎，药物诱导的迟发型皮肤过敏反应，毒性表皮坏死松解症，皮肤T细胞淋巴瘤，大疱性类天疱疮，斑秃，白癜风，痤疮痤疮， 腮腺炎，硬皮病，单纯疱疹病毒或其组合通过施用IL-31单克隆抗体。 本发明进一步提供产生单克隆抗体的杂交瘤。
-
公开(公告)号：US20060275296A1
公开(公告)日：2006-12-07
申请号：US11430066
申请日：2006-05-08
IPC分类号： A61K39/395 , C12N5/06 , C07K16/24
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/76 , C07K2317/92 , Y10S514/885 , Y10S514/886
摘要： The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
摘要翻译： 本发明涉及治疗瘙痒症的方法，包括但不限于接触性皮炎，特应性皮炎，药物诱导的延迟型皮肤过敏反应，毒性表皮坏死松解症，皮肤T细胞淋巴瘤，大疱性类天疱疮，斑秃，白癜风，痤疮红斑痤疮， 腮腺炎，硬皮病，单纯疱疹病毒或其组合通过施用IL-31单克隆抗体。 本发明进一步提供产生单克隆抗体的杂交瘤。
-
公开(公告)号：US09139651B2
公开(公告)日：2015-09-22
申请号：US12986707
申请日：2011-01-07
申请人： Janine Bilsborough
发明人： Janine Bilsborough
IPC分类号： A61K45/00 , A61K39/00 , C07K16/28 , C07K14/715
CPC分类号： C07K16/2866 , A61K39/00 , A61K2039/505 , C07K14/7155 , C07K2317/24 , C07K2317/76
摘要： The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.
摘要翻译： 本发明涉及治疗患有接触性皮炎，药物诱发的延迟型皮肤过敏反应，毒性表皮坏死松解症，皮肤T细胞淋巴瘤，大疱性类天疱疮，秃头症，白癜风，痤疮性红斑痤疮，结节性痒疹，硬皮病，单纯疱疹病毒 ，或通过施用IL-31RA拮抗剂的组合。
-
公开(公告)号：US20110177072A1
公开(公告)日：2011-07-21
申请号：US13075412
申请日：2011-03-30
申请人： Yue Yao , Janine Bilsborough
发明人： Yue Yao , Janine Bilsborough
IPC分类号： A61K39/395 , A61P25/00
CPC分类号： C07K16/244 , A61K38/1793 , A61K39/3955 , A61K2039/505 , C07K16/2866 , C07K2317/14 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/76
摘要： Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
摘要翻译： 使用拮抗剂IL-31用于通过抑制，预防，减少，最小化，限制或最小化神经元组织中的刺激来治疗炎症和疼痛。 这样的拮抗剂包括抗体及其片段，衍生物或变体。 症状如疼痛，刺痛，致敏，与神经病相关的痒症得到改善。
-
公开(公告)号：US20110117052A1
公开(公告)日：2011-05-19
申请号：US12986707
申请日：2011-01-07
申请人： Janine Bilsborough
发明人： Janine Bilsborough
CPC分类号： C07K16/2866 , A61K39/00 , A61K2039/505 , C07K14/7155 , C07K2317/24 , C07K2317/76
摘要： The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.
摘要翻译： 本发明涉及治疗患有接触性皮炎，药物诱发的延迟型皮肤过敏反应，毒性表皮坏死松解症，皮肤T细胞淋巴瘤，大疱性类天疱疮，秃头症，白癜风，痤疮性红斑痤疮，结节性痒疹，硬皮病，单纯疱疹病毒 ，或通过施用IL-31RA拮抗剂的组合。
-
公开(公告)号：US20070238658A1
公开(公告)日：2007-10-11
申请号：US11536461
申请日：2006-09-28
申请人： Steven Levin , Mark Rixon , Zeren Gao , Katherine Lewis , Janine Bilsborough , David Taft
发明人： Steven Levin , Mark Rixon , Zeren Gao , Katherine Lewis , Janine Bilsborough , David Taft
CPC分类号： C07K14/54 , A61K38/00 , A61K2039/505 , C07K16/2866 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/30
摘要： The present invention relates antagonists of IL-17A and IL-17F. The antagonists of the invention are based on IL-17RC alone or on both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RA is a receptor for IL-17A and IL-17RC is a common receptor for both IL-17A and IL-17F. The present invention includes soluble IL-17A and IL-17F antagonists, as well as methods for using the same.
摘要翻译： 本发明涉及IL-17A和IL-17F的拮抗剂。 本发明的拮抗剂基于单独的IL-17RC或IL-17RC和IL-17RA（“IL-17RC / IL-17RA”）两者。 这种拮抗剂用于阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 IL-17RA是IL-17A的受体，IL-17RC是IL-17A和IL-17F的常见受体。 本发明包括可溶性IL-17A和IL-17F拮抗剂，以及使用它们的方法。
-
-
-
-
-
-
-
-
-
搜索结果
47 条记录 (耗时 0.034 秒)
